BOARD OF DIRECTORS
St John Donnie McGrath, M.D., MPH
Dr. McGrath has over 22 years of clinical research and pharmaceutical business development experience.
From 2013 to 2017, he was Vice President, Business Development, and Head of Search & Evaluation at Bristol-Myers Squibb, based in Princeton, NJ. During this period, the business development group executed over 50 major transactions in the therapeutic areas of oncology, neuroscience, cardiovascular, fibrosis, 2 immune-science, virology, and genetically-defined diseases. In addition, Dr. McGrath was responsible for overseeing BMS’ venture capital investment portfolio ($350 million), and provided leadership for all global external partnering activities. From 2010 to 2013, he was Executive Director in Business Development responsible for neuroscience and virology business development. In 2005, he joined the BMS virology clinical development group based in Wallingford, CT, as a director of clinical research, and became Group Director in 2007 and the REYATAZ® Development Lead. Dr. McGrath oversaw multiple clinical virology programs resulting in seven major FDA filings for REYATAZ® and SUSTIVA®, and over 60 EMEA procedures submitted and fulfilled.
From 1998 to 2005, he was a physician-researcher in the Division of Geographic Medicine and Infectious Disease at Tufts-New England Medical Center, and an Assistant Professor of Medicine at Tufts Medical School in Boston. From 2002-2004 he was based at the Africa Center for Reproductive Health and Population Studies in KwaZulu Natal, South Africa, where he established an NIH-funded post-graduate training program in medical informatics with the University of KwaZulu Natal School of Medicine and worked on HIV clinical studies.
Dr. McGrath earned his undergraduate degree at University College Dublin, his medical degree from the Royal College of Surgeons in Ireland, and his MPH from the Harvard School of Public Health. He completed his residency in internal medicine at St. Elizabeth’s Medical Center, and fellowship in Infectious Disease at Tufts-New England Medical Center, both in Boston.Close
David Wang, M.D., Ph.D.
David Wang, M.D., Ph.D., is a Partner and Senior Managing Director on the OrbiMed Asia team, focused on Greater China. Previously, he was a Managing Director at WI Harper Group, responsible for healthcare investments in China. He also previously served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. Dr. Wang was a co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, Dr. Wang was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine. He received his M.D. from Peking University Medical School, and his doctorate in Developmental Biology from California Institute of Technology.Close
Vlad Coric, M.D.
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.Close